AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies using proprietary ²¹²Pb production technology to treat various cancers, including prostate and pancreatic. This approach aims to enhance patient survival and quality of life by delivering precise radiation to tumor cells while minimizing damage to surrounding healthy tissue.
Funding
$20.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MVFounders
Product
Problem
Many cancer treatments lack the precision to target tumor cells effectively, leading to damage of healthy tissue and reduced patient quality of life. Traditional methods of delivering radiation may not be as effective in reaching and destroying cancer cells in various types of tumors.
Solution
AdvanCell is developing targeted alpha therapies using its proprietary ²¹²Pb production technology to address these challenges. This approach involves using alpha particles to deliver precise radiation directly to tumor cells, minimizing damage to surrounding healthy tissue. By targeting the delivery of radiation, AdvanCell aims to improve patient survival rates and enhance their overall quality of life during cancer treatment. The company's vertically integrated approach ensures a consistent and quality-controlled supply of ²¹²Pb, an Active Pharmaceutical Ingredient (API) manufactured to international GMP standards, to accelerate the clinical development of its targeted alpha therapies.
Target Audience
The primary target audience includes cancer patients with solid tumors, oncologists, and medical professionals seeking more effective and targeted cancer treatment options.
Features
- Proprietary ²¹²Pb production technology for a reliable supply of alpha isotopes.
- Targeted alpha therapies designed to deliver radiation directly to cancer cells.
- Vertically integrated manufacturing process ensuring quality control and GMP standards.
- Development pipeline includes therapies for prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary cancers.
- Alpha 212 product, a quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API).